Publicaciones científicas

65 Publicaciones científicas disponibles

  • Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

    8 de septiembre de 2020 | Revista: Cancer Cell

    Catherine S Grasso  1 , Jennifer Tsoi  2 , Mykola Onyshchenko  2 , Gabriel Abril-Rodriguez  2 , Petra Ross-Macdonald  3 , Megan Wind-Rotolo  3 , Ameya Champhekar  2 , Egmidio Medina  2 , Davis Y Torrejon  2 , Daniel Sanghoon Shin  2 , Phuong Tran  2 , Yeon Joo Kim  2 , Cristina Puig-Saus  4 , Katie Campbell  2 , Agustin Vega-Crespo  2 , Michael Quist  2 , Christophe Martignier  5 , Jason J Luke  6 , Jedd D Wolchok  7 , Douglas B Johnson  8 , Bartosz Chmielowski  2 , F Stephen Hodi  9 , Shailender Bhatia  10 , William Sharfman  11 , Walter J Urba  12 , Craig L Slingluff Jr  13 , Adi Diab  14 , John B A G Haanen  15 , Salvador Martin Algarra  16 , Drew M Pardoll  11 , Valsamo Anagnostou  11 , Suzanne L Topalian  11 , Victor E Velculescu  11 , Daniel E Speiser  5 , Anusha Kalbasi  2 , Antoni Ribas  17


  • Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program

    1 de octubre de 2019 | Revista: Melanoma Research

    Salvador Martin-Algarra (1) , Rebecca Hinshelwood (2) , Soizick Mesnage (3) , Jonathan Cebon (4) , Pier Francesco Ferrucci (5) , Massimo Aglietta (6) , Bart Neyns (7) , Vanna Chiarion-Sileni (8) , Colin R Lindsay (9), Michele Del Vecchio (10) , Helen Linardou (11) , Barbara Merelli (12) , Giuseppe Tonini (13) , Victoria Atkinson (14) , Klaus Freivogel (15) , Dara Stein (16) , Lindi Dalland (17) , Mike Lau (18) , Philippe Legenne (18) , Paola Queirolo (19) , Michael Millward (20)

    (1) Department of Medical Oncology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (2) Department of Medical Oncology, The Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW.
    (3) Auckland City Hospital, Auckland, New Zealand.
    (4) Olivia Newton-John Cancer Research Institute at Austin Hospital, Heidelberg, VIC.
    (5) Melanoma Unit, European Institute of Oncology, Milano.
    (6) Department of Medical Oncology, Candiolo Cancer Institute, University of Torino, Torino.
    (7) Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
    (8) Melanoma and Esophageal Cancer Unit, Istituto Oncologico Veneto, Istituto Di Ricovero e Cura a Carattere Scientifico, Padova.
    (9) Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, and Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
    (10) Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
    (11) First Department of Oncology, Metropolitan Hospital, Athens, Greece.
    (12) Department of Medical Oncology, ASST Papa Giovanni XXIII, Bergamo.
    (13) Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome.
    (14) Gallipoli Medical Research Foundation, University of Queensland and Princess Alexandra Hospital, Brisbane, QLD.
    (15) UBC, Lörrach, Germany.
    (16) UBC, Montreal, QC, Canada.
    (17) Novartis Norge AS, Oslo, Norway.
    (18) Novartis Pharma AG, Basel, Switzerland.
    (19) UOC Oncologia Medica, IRCCS San Martino-IST, Genova, Italy.
    (20) School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia.


  • A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain

    21 de agosto de 2019 | Revista: Clinical & Translational Oncology

    Márquez-Rodas I (1,2), Arance A (3), Berrocal A (4), Larios CL (5), Curto-García J (5), Campos-Tapias IX (6), Blanca AB (6), Martin-Algarra S (7).

    (1) Medical Oncology, Hospital General Universitario Gregorio Marañón, Calle Dr. Esquerdo 46, 28007, Madrid, Spain.
    (2) CIBERONC, Madrid, Spain.
    (3) Medical Oncology, Hospital Clínic Barcelona, Barcelona, Spain.
    (4) Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain.
    (5) Clinical Research Department, MFAR S.L, Barcelona, Spain.
    (6) AMGEN S.A, Barcelona, Spain.
    (7) Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.


  • Reality of the emetogenic level of irinotecan

    21 de abril de 2018 | Revista: Support Care Center

    Garcia-Del-Barrio MA (1), Martin-Algarra S (2), Aldaz Pastor A (3).

    (1) Pharmacy Department, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (3) Pharmacy Department, Clínica Universidad de Navarra, Pamplona, Spain.

COVID-19